Skip to main content
Premium Trial:

Request an Annual Quote

Bioké Inks Distribution Agreements With Scale Biosciences, Atrandi Biosciences

NEW YORK – Bioké said this week that it has signed respective distribution agreements for Belgium, the Netherlands, and Luxembourg with Scale Biosciences and Atrandi Biosciences.

ScaleBio, a San Diego-based University of Washington spinout, offers single-cell sequencing and combinatorial indexing technologies.

"By partnering with Bioké, Scale Biosciences can leverage their expertise to offer customers more tailored solutions and support throughout the research process," Melanie Masuda, ScaleBio's director of commercial development, said in a statement.

Lithuania's Atrandi Biosciences, formerly known as Droplet Genomics, offers microfluidics technology. In March, it raised $4.8 million to commercialize its products.

Financial and other terms of the deals were not disclosed.

Netherlands-based Bioké is a subsidiary of Cell Signaling Technology, which acquired Bioké in 2009.

It has signed distribution agreements with several other single-cell technology firms, including Mission Bio and Applied Cells.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.